Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty

Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate t...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Mochida, Yasuhiro [verfasserIn] Ohtake, Takayasu Miyashita, Yusuke Ishioka, Kunihiro Oka, Machiko Maesato, Kyoko Moriya, Hidekazu Hidaka, Sumi Saito, Shigeru Kobayashi, Shuzo

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Schlagwörter:	Atherosclerotic renal artery stenosis (ARAS) Percutaneous transluminal renal angioplasty (PTRA) Renal outcome Mortality Atherosclerosis

Anmerkung:	© The Author(s) 2018

Übergeordnetes Werk:	Enthalten in: Renal replacement therapy - [London] : BioMed Central, 2015, 4(2018), 1 vom: 14. Feb.
Übergeordnetes Werk:	volume:4 ; year:2018 ; number:1 ; day:14 ; month:02

Links:	Volltext

DOI / URN:	10.1186/s41100-018-0147-x

Katalog-ID:	SPR038260646

Internformat


LEADER	01000caa a22002652 4500
001	SPR038260646
003	DE-627
005	20230519195549.0
007	cr uuu---uuuuu
008	201007s2018 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s41100-018-0147-x \|2 doi
035			\|a (DE-627)SPR038260646
035			\|a (SPR)s41100-018-0147-x-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Mochida, Yasuhiro \|e verfasserin \|4 aut
245	1	0	\|a Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2018
520			\|a Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024)
650		4	\|a Atherosclerotic renal artery stenosis (ARAS) \|7 (dpeaa)DE-He213
650		4	\|a Percutaneous transluminal renal angioplasty (PTRA) \|7 (dpeaa)DE-He213
650		4	\|a Renal outcome \|7 (dpeaa)DE-He213
650		4	\|a Mortality \|7 (dpeaa)DE-He213
650		4	\|a Atherosclerosis \|7 (dpeaa)DE-He213
700	1		\|a Ohtake, Takayasu \|4 aut
700	1		\|a Miyashita, Yusuke \|4 aut
700	1		\|a Ishioka, Kunihiro \|4 aut
700	1		\|a Oka, Machiko \|4 aut
700	1		\|a Maesato, Kyoko \|4 aut
700	1		\|a Moriya, Hidekazu \|4 aut
700	1		\|a Hidaka, Sumi \|4 aut
700	1		\|a Saito, Shigeru \|4 aut
700	1		\|a Kobayashi, Shuzo \|4 aut
773	0	8	\|i Enthalten in \|t Renal replacement therapy \|d [London] : BioMed Central, 2015 \|g 4(2018), 1 vom: 14. Feb. \|w (DE-627)866576487 \|w (DE-600)2866852-2 \|x 2059-1381 \|7 nnns
773	1	8	\|g volume:4 \|g year:2018 \|g number:1 \|g day:14 \|g month:02
856	4	0	\|u https://dx.doi.org/10.1186/s41100-018-0147-x \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2018 \|e 1 \|b 14 \|c 02

Indexfelder

author_variant	y m ym t o to y m ym k i ki m o mo k m km h m hm s h sh s s ss s k sk
matchkey_str	article:20591381:2018----::ogemlnclucmoptetwtsvrahrslrtceaatrseoiatrectn
hierarchy_sort_str	2018
publishDate	2018
allfields	10.1186/s41100-018-0147-x doi (DE-627)SPR038260646 (SPR)s41100-018-0147-x-e DE-627 ger DE-627 rakwb eng Mochida, Yasuhiro verfasserin aut Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2018 Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) Atherosclerotic renal artery stenosis (ARAS) (dpeaa)DE-He213 Percutaneous transluminal renal angioplasty (PTRA) (dpeaa)DE-He213 Renal outcome (dpeaa)DE-He213 Mortality (dpeaa)DE-He213 Atherosclerosis (dpeaa)DE-He213 Ohtake, Takayasu aut Miyashita, Yusuke aut Ishioka, Kunihiro aut Oka, Machiko aut Maesato, Kyoko aut Moriya, Hidekazu aut Hidaka, Sumi aut Saito, Shigeru aut Kobayashi, Shuzo aut Enthalten in Renal replacement therapy [London] : BioMed Central, 2015 4(2018), 1 vom: 14. Feb. (DE-627)866576487 (DE-600)2866852-2 2059-1381 nnns volume:4 year:2018 number:1 day:14 month:02 https://dx.doi.org/10.1186/s41100-018-0147-x kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 1 14 02
spelling	10.1186/s41100-018-0147-x doi (DE-627)SPR038260646 (SPR)s41100-018-0147-x-e DE-627 ger DE-627 rakwb eng Mochida, Yasuhiro verfasserin aut Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2018 Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) Atherosclerotic renal artery stenosis (ARAS) (dpeaa)DE-He213 Percutaneous transluminal renal angioplasty (PTRA) (dpeaa)DE-He213 Renal outcome (dpeaa)DE-He213 Mortality (dpeaa)DE-He213 Atherosclerosis (dpeaa)DE-He213 Ohtake, Takayasu aut Miyashita, Yusuke aut Ishioka, Kunihiro aut Oka, Machiko aut Maesato, Kyoko aut Moriya, Hidekazu aut Hidaka, Sumi aut Saito, Shigeru aut Kobayashi, Shuzo aut Enthalten in Renal replacement therapy [London] : BioMed Central, 2015 4(2018), 1 vom: 14. Feb. (DE-627)866576487 (DE-600)2866852-2 2059-1381 nnns volume:4 year:2018 number:1 day:14 month:02 https://dx.doi.org/10.1186/s41100-018-0147-x kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 1 14 02
allfields_unstemmed	10.1186/s41100-018-0147-x doi (DE-627)SPR038260646 (SPR)s41100-018-0147-x-e DE-627 ger DE-627 rakwb eng Mochida, Yasuhiro verfasserin aut Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2018 Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) Atherosclerotic renal artery stenosis (ARAS) (dpeaa)DE-He213 Percutaneous transluminal renal angioplasty (PTRA) (dpeaa)DE-He213 Renal outcome (dpeaa)DE-He213 Mortality (dpeaa)DE-He213 Atherosclerosis (dpeaa)DE-He213 Ohtake, Takayasu aut Miyashita, Yusuke aut Ishioka, Kunihiro aut Oka, Machiko aut Maesato, Kyoko aut Moriya, Hidekazu aut Hidaka, Sumi aut Saito, Shigeru aut Kobayashi, Shuzo aut Enthalten in Renal replacement therapy [London] : BioMed Central, 2015 4(2018), 1 vom: 14. Feb. (DE-627)866576487 (DE-600)2866852-2 2059-1381 nnns volume:4 year:2018 number:1 day:14 month:02 https://dx.doi.org/10.1186/s41100-018-0147-x kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 1 14 02
allfieldsGer	10.1186/s41100-018-0147-x doi (DE-627)SPR038260646 (SPR)s41100-018-0147-x-e DE-627 ger DE-627 rakwb eng Mochida, Yasuhiro verfasserin aut Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2018 Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) Atherosclerotic renal artery stenosis (ARAS) (dpeaa)DE-He213 Percutaneous transluminal renal angioplasty (PTRA) (dpeaa)DE-He213 Renal outcome (dpeaa)DE-He213 Mortality (dpeaa)DE-He213 Atherosclerosis (dpeaa)DE-He213 Ohtake, Takayasu aut Miyashita, Yusuke aut Ishioka, Kunihiro aut Oka, Machiko aut Maesato, Kyoko aut Moriya, Hidekazu aut Hidaka, Sumi aut Saito, Shigeru aut Kobayashi, Shuzo aut Enthalten in Renal replacement therapy [London] : BioMed Central, 2015 4(2018), 1 vom: 14. Feb. (DE-627)866576487 (DE-600)2866852-2 2059-1381 nnns volume:4 year:2018 number:1 day:14 month:02 https://dx.doi.org/10.1186/s41100-018-0147-x kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 1 14 02
allfieldsSound	10.1186/s41100-018-0147-x doi (DE-627)SPR038260646 (SPR)s41100-018-0147-x-e DE-627 ger DE-627 rakwb eng Mochida, Yasuhiro verfasserin aut Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2018 Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) Atherosclerotic renal artery stenosis (ARAS) (dpeaa)DE-He213 Percutaneous transluminal renal angioplasty (PTRA) (dpeaa)DE-He213 Renal outcome (dpeaa)DE-He213 Mortality (dpeaa)DE-He213 Atherosclerosis (dpeaa)DE-He213 Ohtake, Takayasu aut Miyashita, Yusuke aut Ishioka, Kunihiro aut Oka, Machiko aut Maesato, Kyoko aut Moriya, Hidekazu aut Hidaka, Sumi aut Saito, Shigeru aut Kobayashi, Shuzo aut Enthalten in Renal replacement therapy [London] : BioMed Central, 2015 4(2018), 1 vom: 14. Feb. (DE-627)866576487 (DE-600)2866852-2 2059-1381 nnns volume:4 year:2018 number:1 day:14 month:02 https://dx.doi.org/10.1186/s41100-018-0147-x kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 1 14 02
language	English
source	Enthalten in Renal replacement therapy 4(2018), 1 vom: 14. Feb. volume:4 year:2018 number:1 day:14 month:02
sourceStr	Enthalten in Renal replacement therapy 4(2018), 1 vom: 14. Feb. volume:4 year:2018 number:1 day:14 month:02
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Atherosclerotic renal artery stenosis (ARAS) Percutaneous transluminal renal angioplasty (PTRA) Renal outcome Mortality Atherosclerosis
isfreeaccess_bool	true
container_title	Renal replacement therapy
authorswithroles_txt_mv	Mochida, Yasuhiro @@aut@@ Ohtake, Takayasu @@aut@@ Miyashita, Yusuke @@aut@@ Ishioka, Kunihiro @@aut@@ Oka, Machiko @@aut@@ Maesato, Kyoko @@aut@@ Moriya, Hidekazu @@aut@@ Hidaka, Sumi @@aut@@ Saito, Shigeru @@aut@@ Kobayashi, Shuzo @@aut@@
publishDateDaySort_date	2018-02-14T00:00:00Z
hierarchy_top_id	866576487
id	SPR038260646
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR038260646</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519195549.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s41100-018-0147-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR038260646</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s41100-018-0147-x-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mochida, Yasuhiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2018</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atherosclerotic renal artery stenosis (ARAS)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Percutaneous transluminal renal angioplasty (PTRA)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Renal outcome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mortality</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atherosclerosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohtake, Takayasu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miyashita, Yusuke</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishioka, Kunihiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oka, Machiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maesato, Kyoko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moriya, Hidekazu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hidaka, Sumi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saito, Shigeru</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kobayashi, Shuzo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Renal replacement therapy</subfield><subfield code="d">[London] : BioMed Central, 2015</subfield><subfield code="g">4(2018), 1 vom: 14. Feb.</subfield><subfield code="w">(DE-627)866576487</subfield><subfield code="w">(DE-600)2866852-2</subfield><subfield code="x">2059-1381</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">day:14</subfield><subfield code="g">month:02</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s41100-018-0147-x</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="b">14</subfield><subfield code="c">02</subfield></datafield></record></collection>
author	Mochida, Yasuhiro
spellingShingle	Mochida, Yasuhiro misc Atherosclerotic renal artery stenosis (ARAS) misc Percutaneous transluminal renal angioplasty (PTRA) misc Renal outcome misc Mortality misc Atherosclerosis Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
authorStr	Mochida, Yasuhiro
ppnlink_with_tag_str_mv	@@773@@(DE-627)866576487
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2059-1381
topic_title	Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty Atherosclerotic renal artery stenosis (ARAS) (dpeaa)DE-He213 Percutaneous transluminal renal angioplasty (PTRA) (dpeaa)DE-He213 Renal outcome (dpeaa)DE-He213 Mortality (dpeaa)DE-He213 Atherosclerosis (dpeaa)DE-He213
topic	misc Atherosclerotic renal artery stenosis (ARAS) misc Percutaneous transluminal renal angioplasty (PTRA) misc Renal outcome misc Mortality misc Atherosclerosis
topic_unstemmed	misc Atherosclerotic renal artery stenosis (ARAS) misc Percutaneous transluminal renal angioplasty (PTRA) misc Renal outcome misc Mortality misc Atherosclerosis
topic_browse	misc Atherosclerotic renal artery stenosis (ARAS) misc Percutaneous transluminal renal angioplasty (PTRA) misc Renal outcome misc Mortality misc Atherosclerosis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Renal replacement therapy
hierarchy_parent_id	866576487
hierarchy_top_title	Renal replacement therapy
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)866576487 (DE-600)2866852-2
title	Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
ctrlnum	(DE-627)SPR038260646 (SPR)s41100-018-0147-x-e
title_full	Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
author_sort	Mochida, Yasuhiro
journal	Renal replacement therapy
journalStr	Renal replacement therapy
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
author_browse	Mochida, Yasuhiro Ohtake, Takayasu Miyashita, Yusuke Ishioka, Kunihiro Oka, Machiko Maesato, Kyoko Moriya, Hidekazu Hidaka, Sumi Saito, Shigeru Kobayashi, Shuzo
container_volume	4
format_se	Elektronische Aufsätze
author-letter	Mochida, Yasuhiro
doi_str_mv	10.1186/s41100-018-0147-x
title_sort	long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
title_auth	Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
abstract	Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) © The Author(s) 2018
abstractGer	Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) © The Author(s) 2018
abstract_unstemmed	Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024) © The Author(s) 2018
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty
url	https://dx.doi.org/10.1186/s41100-018-0147-x
remote_bool	true
author2	Ohtake, Takayasu Miyashita, Yusuke Ishioka, Kunihiro Oka, Machiko Maesato, Kyoko Moriya, Hidekazu Hidaka, Sumi Saito, Shigeru Kobayashi, Shuzo
author2Str	Ohtake, Takayasu Miyashita, Yusuke Ishioka, Kunihiro Oka, Machiko Maesato, Kyoko Moriya, Hidekazu Hidaka, Sumi Saito, Shigeru Kobayashi, Shuzo
ppnlink	866576487
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/s41100-018-0147-x
up_date	2024-07-03T17:03:21.203Z
_version_	1803578193954734081
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR038260646</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519195549.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s41100-018-0147-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR038260646</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s41100-018-0147-x-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mochida, Yasuhiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2018</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background In the patients with severe atherosclerotic renal artery stenosis (ARAS), the evaluation of long-term clinical outcome after percutaneous transluminal renal angioplasty (PTRA) has yet been insufficient. The aim of this study was to focus on only patients with severe ARAS and to evaluate the more long-term clinical outcome after PTRA. Methods We performed a single-center retrospective review of the outcome after PTRA. All eligible patients had ARAS of ≥ 75% by catheter renal angiography and underwent PTRA in our hospital from July 2004 to December 2007. We investigated long-term changes of renal function and the other clinical outcomes in patients with severe ARAS. Results The median follow-up period was 83 months. The overall mean stenosis rate was 87%. There were 24 patients with 75 ≤ and < 90%, 38 patients with 90 ≤ and < 95%, and 12 patients with ≥ 95% stenosis. Serum creatinine(S-Cr) levels were from 1.27 ± 0.68 at baseline to 1.33 ± 0.65 mg/dl at 84 months after PTRA in overall (p = 0.255). The renal size was also preserved for long-term in overall. Although serum creatinine level in patients with renal major axis < 85 mm at PTRA significantly increased (p < 0.05) after 60 months post PTRA, it did not worsen in patients with renal major axis more than 85 mm during observational period. The number of anti-hypertension drugs decreased from baseline (p = 0.0037), and both systolic and diastolic blood pressure significantly decreased (p < 0.001) after PTRA. Finally, 4 patients had renal death, and 14 patients died. Overall survival for 60 months was 85%. Conclusions We demonstrated that PTRA for patients with severe ARAS significantly decreased blood pressure, and preserved renal function and renal size for long term. Trial registration This study was admitted by Tokushukai Group Institutional Review Board. (IRB no. TGE00532-024)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atherosclerotic renal artery stenosis (ARAS)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Percutaneous transluminal renal angioplasty (PTRA)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Renal outcome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mortality</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Atherosclerosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohtake, Takayasu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miyashita, Yusuke</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishioka, Kunihiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oka, Machiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maesato, Kyoko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moriya, Hidekazu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hidaka, Sumi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saito, Shigeru</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kobayashi, Shuzo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Renal replacement therapy</subfield><subfield code="d">[London] : BioMed Central, 2015</subfield><subfield code="g">4(2018), 1 vom: 14. Feb.</subfield><subfield code="w">(DE-627)866576487</subfield><subfield code="w">(DE-600)2866852-2</subfield><subfield code="x">2059-1381</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">day:14</subfield><subfield code="g">month:02</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s41100-018-0147-x</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="b">14</subfield><subfield code="c">02</subfield></datafield></record></collection>
score	7.399496

Nicht das Richtige dabei?

Schreiben Sie uns!

Long-term clinical outcome of patients with severe atherosclerotic renal artery stenosis after percutaneous transluminal renal angioplasty

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?